Dr. Andrea Sautter

Andrea is member of the Practice Area Patents Technology & Life Sciences and the Life Sciences & Healthcare Industry Group.

Her practice includes advising national and international pharmaceutical and biotech companies, medical product manufacturers and food product producers on intellectual property law and regulatory issues. A focus of her practice is advising on complex, often cross-border, projects, in particular research and development cooperations, manufacturing and distribution agreements and licences, as well as advice on transactions.

Show full CV Hide full CV

Career

Since 2020	Salary Partner, Taylor Wessing
2015 – 2019	Senior Associate, Taylor Wessing
Since 2012	Lecturer for presentation methods, University of Mannheim

2010 – 2012

Research and teaching Assistant, Institute for Medical Law of the Universities of Heidelberg and Mannheim (IMGB)

More Less

Education

2018	Ph.D. in law, University of Mannheim
2015	Admitted as a lawyer, Munich
2015	Second state examination, Wiesbaden

2013 – 2015	Legal clerkship including stages at an international law firm in Frankfurt; the legal department of a healthcare corporation in Bad Homburg v.d.H and the German Desk of a Korean law firm in Seoul
2012	Additional qualification in pharmaceutical law, University in Marburg
2010	First state examination
2005 – 2010	Legal studies, University of Mannheim

More Less

Additional languages

English

Expertise

Services and Groups Patents & innovation

Sectors Life sciences & healthcare Biotech Cosmetics, food nutrition & supplements Medical devices Pharmaceuticals

Experience

Formycon	Under the leadership of the Frankfurt-based Taylor-Wessing partners Lars-Gerrit Lüßmann and Michael Sinhart, Formycon AG and ATHOS KG are merging their development activities in the field of so-called biosimilars, the follow-up products of biological medicines (biologics), in a long-term strategic partnership. The centrepiece of this agreement is Formycon AG’s participation in the rights of two biosimilars. The volume of the legally complex transaction (aggregate counter-performance) adds up to approximately 650 million euros.
Hauck & Aufhäuser	A Taylor Wessing team led by Frankfurt-based partners Lars-Gerrit Lüßmann and Ulrich Reers advised Hauck & Aufhäuser Investment Banking and Polish universal bank mBank in their role as exchange trustee and settlement agent on the voluntary public takeover/exchange offer by Frankfurt-listed Vita 34 AG, Leipzig, to the shareholders of Warsaw-listed stem cell bank Polski Bank Komórek Macierzystych S.A, Warsaw (PBKM). The transaction is the first cross-border exchange offer for a Polish listed company to date.
Steadfast Capital Fund IV on the acquisition of a majority stake in Söhngen Group	Steadfast Capital Fund IV on the acquisition of a majority stake in Söhngen Group. The transaction included both W. Söhngen GmbH based in Taunusstein (Hesse) and Silva GmbH based in Mainhausen (Hesse). The parties have agreed not to disclose the purchase price. The majority acquisition aims to support further growth of the Söhngen Group with its internationally recognised brands and premium products in the market for first aid and emergency medical products both organically and through acquisitions. We also advised on the financing of the acquisition.

Latest news & insights

Patents & innovation

EU Health Technology Assessment (HTA) Regulation (2021/2282) of January 11, 2022.

Background: History of the HTA Regulation

12 September 2022

Briefing

by Dr. Andrea Sautter

Click here to find out more

Digital health

Digital Nursing Applications as a further step towards future-oriented health care provision

12 September 2022

Briefing

by Dr. Andrea Sautter

Click here to find out more

Corporate/M&A & capital markets

Taylor Wessing advises Azenta Life Sciences on the acquisition of the Barkey Group

17 June 2022

by multiple authors

Click here to find out more

Interface - FoodTech

Innovations in Food Production: EU plans a new legal framework for genome-edited plants

With a new legal framework, the EU is trying to catch up with the state of development of new genomic techniques. At present, they are subject to the rigid regulatory regime of Genetic Engineering Law, and haste is called for.

25 April 2022

Briefing

by Dr. Andrea Sautter

1 of 4 Insights

Click here to find out more

See all insights

Related people

Prev. Next